ALK and autoimmune thrombocytopenic purpura: It opens options for further drug repurposing, potentially considering all available inhibitors against ALK to be used against LTK-positive cells, and, in particular, in cases of B-cell dependent disorders, such as autoimmune diseases (e.g., immune thrombocytopenia) or cancer (e.g., multiple myeloma).